Terms: = Ovarian cancer AND TOP2A, TOP2, TP2A AND Diagnosis
8 results:
1. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing top2a mRNA.
Cui S; Li F
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34414458
[TBL] [Abstract] [Full Text] [Related]
2. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract] [Full Text] [Related]
3. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract] [Full Text] [Related]
4. ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.
Botti G; Malzone MG; La Mantia E; Montanari M; Vanacore D; Rossetti S; Quagliariello V; Cavaliere C; Di Franco R; Castaldo L; Ametrano G; Cappuccio F; Romano FJ; Piscitelli R; Pepe MF; D'Aniello C; Facchini G
Int J Med Sci; 2017; 14(6):554-559. PubMed ID: 28638271
[TBL] [Abstract] [Full Text] [Related]
5. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of top2a as a Predictive Marker for Endometrial cancer With Taxane-Containing Adjuvant Chemotherapy.
Ito F; Furukawa N; Nakai T
Int J Gynecol Cancer; 2016 Feb; 26(2):325-30. PubMed ID: 26588239
[TBL] [Abstract] [Full Text] [Related]
7. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract] [Full Text] [Related]
8. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Zajchowski DA; Karlan BY; Shawver LK
Mol Cancer Ther; 2012 Feb; 11(2):492-502. PubMed ID: 22203729
[TBL] [Abstract] [Full Text] [Related]